Biogen enrolls patients in new MS trial - Boston Business Journal:

Wood ceiling
The trial, called ADVANCE, will determine the efficacy and safethof Biogen’s drug target, called PEGylated interferon beta-1a, in reducing relapsee rates in patients with multiple sclerosis (RMS). The globaol study will enroll morethan 1,200 patients with RMS between the ages of 18 and 55. The study’sa goal is to determinee whether the drug reduces the annualizedf relapse rate in patients with RMS at one The study will alsoexaminee if, over time, the potentiao treatment can slow disease progression and lead to a decreasw in the number of a certain kind of braihn lesions commonly seen in MS The treatment is a combination of Interferon which has been used successfully to treag MS for more than 10 years, and PEGylation, whichn can extend the amount of time a drug remainds in a patient’s system.
If the trialk is successful, the treatmenf has the potential to reduce the frequency of treatmentf injections and provide patients with an effective and more convenientgdosing option. Biogen’s (NASDAQ: BIIB) stocl was trading at in $49.33 in morning tradinvg on Monday, down from the previous close of $51.67.